Across the recent three months, 4 analysts have shared their insights on Pharming PHAR, expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ...

Explore Pharming stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PHAR. European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study ...

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a ...

Pharming Group delivered strong financial results in Q4 2024 and provided an optimistic 2025 revenue guidance of $315 million to $335 million, driven by the continued success of RUCONEST and Joenja.

Oppenheimer raised the firm’s price target on Pharming (PHAR) to $39 from $30 and keeps an Outperform rating on the shares following quarterly results. The firm notes 2024 revenue of $297M came ...

(RTTNews) - Pharming Group N.V. (PHAR), a global biopharmaceutical company, on Thursday reported profit for the fourth quarter compared with loss last year. In the fourth quarter, net income came ...

Pharming Group has a 52-week low of $6.65 and a 52-week high of $11.94. The stock has a market capitalization of $541.53 million, a P/E ratio of -30.62 and a beta of -0.10. Get Pharming Group alerts: ...

Pharming has submitted its oral phosphoinositide 3-kinase delta (PI3Kδ) inhibitor leniolisib for approval in the EU as a treatment for activated PI3K delta syndrome (APDS), an ultra-rare disease ...

Good day and thank you for standing by. Welcome to the Pharming Group Fourth Quarter and Full-year 2024 Results Conference Call and Webcast. [Operator Instructions] Please be advised that today's ...

adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, in line with our vision to become a leading global rare disease company ...

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of ...